Devextinetug Biosimilar - Research Grade

Human

methamphetamine [Drug]

>1mg/ml

IgG2 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product (ICH5477) is offered as a research-grade biosimilar of Devextinetug: an unconjugated, non-therapeutic analog of the originator antibody, produced for research use only (RUO). Like other ichor.bio biosimilars it is intended as a functional research tool rather than a clinical drug, and is supplied unconjugated at research-grade purity for in-vitro and functional applications. The card lists the molecule as a human IgG2-kappa antibody directed against methamphetamine as its target, which would place it in the class of anti-drug (hapten-sequestering) antibodies raised against a small-molecule drug of abuse rather than a protein antigen. Importantly, "Devextinetug" could not be independently verified against a recognized INN record, and the pairing of this drug name with a methamphetamine target could not be confirmed, so the description here is deliberately conservative. Investigators should confirm the exact originator, target specificity, and intended application against primary sources and the certificate of analysis before use. As a biosimilar analog it is positioned for binding, neutralization, and control experiments rather than therapeutic dosing. The listed target, methamphetamine, is a small-molecule psychostimulant (an amphetamine derivative), not a protein antigen. It is a hapten: too small to be immunogenic on its own, so antibodies against it are typically generated using carrier-conjugated derivatives. Anti-methamphetamine antibodies are studied as pharmacokinetic-based sequestering agents that bind circulating drug, redistribute it away from the central nervous system, and blunt its stimulant and reinforcing effects, an approach explored for stimulant use disorder and overdose. Because the antigen is a diffusible small molecule rather than a cell-surface or soluble protein target, relevant assays center on affinity, capacity, and specificity of drug binding rather than receptor or pathway engagement. Given that this drug/target pairing could not be independently verified, the biology described should be treated as the target-class rationale rather than a confirmed characterization of this specific product.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Devextinetug (anti-methamphetamine [Drug]) Biosimilar

Q: Is the Devextinetug biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Devextinetug biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Devextinetug biosimilar target?

A: It is a non-therapeutic research analog of Devextinetug that binds methamphetamine [Drug]; for research use only.